Logo
x

Search

Subscribe Now

Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

Apellis' Empaveli (pegcetacoplan) Receives the US FDA's Approval for Paroxysmal Nocturnal Hemoglobinuria

  • May 17, 2021
Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

Alexion's Ultomiris (ravulizumab) Receives the CHMP's Positive Opinion for its New Advanced Formulation

  • September 22, 2020
Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

Novartis Reports Results of LNP023 in P-II Study for Paroxysmal Nocturnal Hemoglobinuria

  • August 31, 2020
Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria

Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria

  • September 25, 2019
Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar- eculizumab) to Treat Paroxysmal Nocturnal Hemoglobinuria (PNH) in India

Samsung Bioepis Initiates Recruitment of Patients in P-III Study for SB12 (biosimilar- eculizumab) to Treat Paroxysmal Nocturnal H...

  • August 16, 2019
Alexion's Ultomiris (Ravulizumab) Receives European Commission's Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria in Adults

Alexion's Ultomiris (Ravulizumab) Receives European Commission's Marketing Authorization for Paroxysmal Nocturnal Hemoglobinuria i...

  • July 4, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.